ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
The new assay consolidates screening for four major viral threats into a single workflow
Subscribe To Our Newsletter & Stay Updated
